newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia

Plans to Complete Submission by the End of the First Quarter of 2022 If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich's Ataxia Reata Pharmaceuticals, Inc. (NASDAQ:RETA), ("Reata," th